PepGenexShop our research products

Net peptide content

Net peptide content, also reported as peptide content or peptide mass fraction, is the proportion of the mass of a solid peptide material that is the peptide itself, as distinct from counterions, water, residual solvents and inorganic residue weighed along with it. A review of counter-ions in peptides lists peptide concentration or mass fraction, residual solvents such as water, and counter-ions among the characteristics that quality control of a synthetic peptide should determine, alongside identity and purity.[1],[2]

What else makes up the mass of a peptide powder?

Sikora and colleagues state that synthesis by the Fmoc/t-butyl solid-phase approach followed by reversed-phase HPLC purification leads to peptides as trifluoroacetate salts, and that trifluoroacetate can be present either bound to basic residues or adsorbed in the lyophilizate as a contaminant.[1]

In a 2025 study of four synthetic peptides, Erckes and colleagues measured trifluoroacetate at up to 35% and chloride at up to 10% of the total mass of the peptide salts, while sodium stayed below 0.5%.[3]

In the mass balance scheme described by McCarthy and colleagues, water is measured by the Karl Fischer method, residual solvents testing accounts for solvents left from production, and residue on ignition accounts for inorganic impurities.[2]

How does amino acid analysis measure peptide content?

Stoppacher and colleagues describe it as common practice to quantify the mass concentration of a peptide solution by measuring selected chemically stable amino acids released by complete hydrolysis, because there is generally too little material for a direct purity characterization of the intact peptide.[4]

Wang and colleagues reported a version in which hydrolysis is followed by reversed-phase liquid chromatography with stable isotope dilution mass spectrometry, choosing two or more amino acids per peptide to support accuracy, with relative standard deviations below 8% and relative errors below 5%.[5]

The method counts amino acids, not intact molecules. In the angiotensin I material Stoppacher and colleagues examined, structurally related impurities made up an estimated 10.4 mg/g, and failing to correct for them would have produced a 1% error in a concentration determined by amino acid analysis.[4]

What does quantitative NMR add?

Melanson and colleagues describe amino acid analysis by isotope dilution tandem mass spectrometry after hydrolysis as the conventional reference method, and quantitative nuclear magnetic resonance (qNMR) as a way to quantify the intact peptide that removes potential bias from the hydrolysis step.[6]

The same authors note that both methods are susceptible to interference from related peptide impurities, which have to be measured and accounted for, and they combined the two with a mass balance result to assign a value of 691 ± 9 mg/g to a candidate angiotensin II reference material.[6]

For angiotensin I reference materials, Deng and colleagues assessed purity by mass balance and by qNMR with maleic acid as the internal standard, verified the final value by isotope dilution mass spectrometry, and reported purities of 0.8511 and 0.8696 g/g for the natural and isotope-labeled materials.[7]

What is the mass balance approach?

In the mass balance approach, as Stoppacher and colleagues describe it, a range of analytical techniques estimates the mass fraction of every impurity present, and the mass fraction of the main peptide is assigned as the difference from the theoretical limit.[4]

Deng and colleagues illustrate the separate measurements involved: moisture by the Karl Fischer method, anion content by ion chromatography and inorganic elements by inductively coupled plasma mass spectrometry.[7]

McCarthy and colleagues, describing pharmacopeial peptide reference standards, write that there are multiple methods for establishing peptide content and that approaches continue to evolve, and report that in their strategy a mass balance approach gave the least inter-laboratory variability.[2]

Can peptide content be measured from elemental composition?

Cueto Díaz and colleagues described a method in which the peptide is separated from related impurities by liquid chromatography, oxidized online to carbon dioxide and measured by carbon isotope dilution mass spectrometry, so that peptide content is quantified from its carbon content against a generic primary standard, potassium hydrogen phthalate.[8]

They validated the approach with a reference material, NIST 8327, and compared results for two commercial synthetic peptide standards with those from amino acid analysis and from inductively coupled plasma mass spectrometry.[8]

Why does water content change the figure?

McCarthy and colleagues adjust a mass balance purity to an as-is basis using the water content of each laboratory's own portion of material, to account for differences in humidity during testing, and measure water at the time the HPLC analysis is prepared.[2]

The same report states that many pharmacopeial peptide reference standards were moved from powdered to lyophilized form to remove the need for the user to determine counter-ions and residual moisture before use.[2]

Limitations

A peptide content figure depends on the method behind it. Melanson and colleagues note that both amino acid analysis and qNMR can be biased by related peptide impurities unless those are measured separately.[6]

Peptide content is a quantity, not an identity result or a chromatographic purity result; ICH Q6B handles identity and purity as separate specification items with their own tests.[9]

The figures quoted here describe the particular materials in the cited studies, including angiotensin reference materials, and say nothing about the content of any other material.[4],[6],[7],[3]

This page describes what the cited documents say. It is not a statement that any PepGenex material has been manufactured, tested or released under any of them.

Compound profiles

Sermorelin, tesamorelin and thymalfasin (thymosin alpha-1) appear as acetate salts in the table compiled by Sikora and colleagues, so a weighed sample of each includes its counterion alongside the peptide.[1]

References

  1. Sikora K, Jaśkiewicz M, Neubauer D, Migoń D, Kamysz W. The Role of Counter-Ions in Peptides-An Overview. Pharmaceuticals (Basel). 2020;13(12):442. PMID 33287352 · DOI 10.3390/ph13120442 · PMC7761850
  2. McCarthy D, Han Y, Carrick K, et al. Reference Standards to Support Quality of Synthetic Peptide Therapeutics. Pharm Res. 2023;40(6):1317-1328. PMID 36949371 · DOI 10.1007/s11095-023-03493-1 · PMC10338602
  3. Erckes V, Streuli A, Chamera Rendueles L, Krämer SD, Steuer C. Towards a Consensus for the Analysis and Exchange of TFA as a Counterion in Synthetic Peptides and Its Influence on Membrane Permeation. Pharmaceuticals (Basel). 2025;18(8):1163. PMID 40872554 · DOI 10.3390/ph18081163 · PMC12389442
  4. Stoppacher N, Josephs RD, Daireaux A, et al. Impurity identification and determination for the peptide hormone angiotensin I by liquid chromatography-high-resolution tandem mass spectrometry and the metrological impact on value assignments by amino acid analysis. Anal Bioanal Chem. 2013;405(25):8039-8051. PMID 23708692 · DOI 10.1007/s00216-013-6953-7
  5. Wang X, Qin W, Qian X, Zhang Y. Accurate quantification of synthetic peptides by amino acid-stable isotope dilution mass spectrometry [article in Chinese]. Se Pu. 2012;30(3):239-244. PMID 22715687 · DOI 10.3724/sp.j.1123.2012.01035
  6. Melanson JE, Thibeault MP, Stocks BB, et al. Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem. 2018;410(26):6719-6731. PMID 30143839 · DOI 10.1007/s00216-018-1272-7
  7. Deng F, Wang R, Liu K, et al. Development and characterization of angiotensin I certified reference materials. Anal Bioanal Chem. 2025;417(19):4395-4406. PMID 40536667 · DOI 10.1007/s00216-025-05955-4
  8. Cueto Díaz S, Ruiz Encinar J, García Alonso JI. Evaluation of online carbon isotope dilution mass spectrometry for the purity assessment of synthetic peptide standards. Anal Chim Acta. 2014;844:48-53. PMID 25172815 · DOI 10.1016/j.aca.2014.07.041
  9. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. U.S. FDA guidance for industry, August 1999. FDA docket FDA-1998-D-0003